Amlodipine And Olmesartan Medoxomil Tablet
FDA Recall NDC 67877-501
FDA Enforcement Report: View Recall Date, Reasons, and Safety Status
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Amlodipine And Olmesartan Medoxomil (NDC 67877-501). A significant event, classified as Class II, was initiated on Jul 21, 2025 by Ascend Laboratories, Llc. The reported reason for this action was: "Failed Dissolution Specifications: low dissolution results"
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class II Ongoing
Failed Dissolution Specifications: low dissolution results
Jul 21, 2025
Aug 20, 2025
8,568 bottles
Recall Profile & Regulatory Data
Event ID
97293
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ascend Laboratories, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/ 40 mg, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-501-30
Batch or Lot Expiration Information
Lot# Lot 23121560, Exp 4/30/2026
Affected Packages Involved in this Recall
67877-499-30Product
67877-499-90Product
67877-500-30Product
67877-500-90Product
67877-501-30Product
67877-501-90Product
67877-502-30Product
67877-502-90Product
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
